Literature DB >> 28786069

The value of transvaginal ultrasound in clinical surgical treatment of cesarean scar pregnancy.

Zhen Zeng1, Shu-Ping Ding1, Xue Zeng1, Sui Cao1, Ling-Yu Wei1, Yan-Yan Liu1, Fu-Yan Yang1, Jing-Ji Gong1, Han-Ping Chen1, Xiao-Yan Xu2.   

Abstract

The clinical value of transvaginal ultrasound in clinical surgical treatment of cesarean scar pregnancy (CSP) was evaluated. The clinical data of 104 patients with CSP admitted at Tongji Hospital from 2013 to 2016 were collected and analyzed retrospectively, including the patients' age, gestational age, the size of gestational sac or uneven mass, the uterine scar thickness, β human chorionic gonadotropin (hCG) levels and so on. Of these 104 cases, 30 cases were subjected to laparotomy, 29 cases to laparoscopy, 27 cases to hysteroscopy, 16 cases to ultrasound-guided uterine curettage, and 2 cases to conservative treatment. The transvaginal ultrasound showed that uterine scar thickness and gestational sac or uneven mass size had significant difference (P<0.05) among different surgical methods by comparatively analyzing the patients' data. It was suggested that transvaginal ultrasound may provide the valuable reference for choosing clinical surgical procedures for CSP.

Entities:  

Keywords:  cesarean scar pregnancy; clinical surgical treatment; transvaginal ultrasound

Mesh:

Year:  2017        PMID: 28786069     DOI: 10.1007/s11596-017-1769-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  21 in total

Review 1.  Ectopic pregnancies in a Caesarean scar: review of the medical approach to an iatrogenic complication.

Authors:  R Maymon; R Halperin; S Mendlovic; D Schneider; A Herman
Journal:  Hum Reprod Update       Date:  2004-09-16       Impact factor: 15.610

2.  Cesarean scar ectopic pregnancies: etiology, diagnosis, and management.

Authors:  Michael A Rotas; Shoshana Haberman; Michael Levgur
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

3.  Outcomes of primary surgical evacuation during the first trimester in different types of implantation in women with cesarean scar pregnancy.

Authors:  Ling-Yun Cheng; Chen-Bin Wang; Li-Ching Chu; Chih-Wen Tseng; Fu-Tsai Kung
Journal:  Fertil Steril       Date:  2014-08-11       Impact factor: 7.329

Review 4.  Cesarean scar pregnancy and early placenta accreta share common histology.

Authors:  I E Timor-Tritsch; A Monteagudo; G Cali; J M Palacios-Jaraquemada; R Maymon; A A Arslan; N Patil; D Popiolek; K R Mittal
Journal:  Ultrasound Obstet Gynecol       Date:  2014-04       Impact factor: 7.299

5.  The diagnosis, treatment, and follow-up of cesarean scar pregnancy.

Authors:  Ilan E Timor-Tritsch; Ana Monteagudo; Rosalba Santos; Tanya Tsymbal; Grace Pineda; Alan A Arslan
Journal:  Am J Obstet Gynecol       Date:  2012-04-16       Impact factor: 8.661

6.  Pregnancy in a uterine scar sacculus--an unusual cause of postabortal haemorrhage. A case report.

Authors:  J V Larsen; M H Solomon
Journal:  S Afr Med J       Date:  1978-01-28

7.  An ectopic pregnancy developing in a previous caesarian section scar.

Authors:  P A Godin; S Bassil; J Donnez
Journal:  Fertil Steril       Date:  1997-02       Impact factor: 7.329

8.  Is methotrexate administration needed for the treatment of caesarean section scar pregnancy in addition to suction curettage?

Authors:  Osman Sevket; Seda Keskin; Seda Ates; Taner Molla; Ramazan Dansuk; Hasan Fehmi Yazicioglu; Oguz Yucel
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-01-27       Impact factor: 1.848

9.  Bilateral uterine artery chemoembolization with methotrexate for cesarean scar pregnancy.

Authors:  Licong Shen; Aixiang Tan; Huili Zhu; Chun Guo; Dong Liu; Wei Huang
Journal:  Am J Obstet Gynecol       Date:  2012-09-17       Impact factor: 8.661

10.  Comparative efficacy and safety of local and systemic methotrexate injection in cesarean scar pregnancy.

Authors:  Ping Peng; Ting Gui; Xinyan Liu; Weilin Chen; Zhenzhen Liu
Journal:  Ther Clin Risk Manag       Date:  2015-01-27       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.